2-fluoro-N-(1-hydroxy-1,3-dihydro-benzo[c][1,2]oxaborol-6-yl)-4-trifluoromethyl-benzamide | 1222509-14-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-fluoro-N-(1-hydroxy-1,3-dihydro-benzo[c][1,2]oxaborol-6-yl)-4-trifluoromethyl-benzamide
• 英文别名: 2-fluoro-N-(1-hydroxy-3H-2,1-benzoxaborol-6-yl)-4-(trifluoromethyl)benzamide
• CAS: 1222509-14-9
• 化学式: C₁₅H₁₀BF₄NO₃
• 分子量: 339.054
• InChiKey: GGGWVCPPTQVWSE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.31
• 重原子数：
  24
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.13
• 拓扑面积：
  58.6
• 氢给体数：
  2
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  2-氟-4-(三氟甲基)苯甲酰氯 、 1,3-二氢-1-羟基-2,1-苯并噁硼-6-胺 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 生成 2-fluoro-N-(1-hydroxy-1,3-dihydro-benzo[c][1,2]oxaborol-6-yl)-4-trifluoromethyl-benzamide
  参考文献：
  名称：

  Discovery and structure–activity relationships of 6-(benzoylamino)benzoxaboroles as orally active anti-inflammatory agents

  摘要：

  Structure-activity relationships of 6-(benzoylamino)benzoxaborole analogs were investigated for the inhibition of TNF-alpha, IL-1 beta, and IL-6 from lipopolysaccharide stimulated peripheral blood mononuclear cells. Compound 1q showed potent activity against all three cytokines with IC50 values between 0.19 and 0.50 mu M, inhibited LPS-induced TNF-alpha and IL-6 elevation in mice and improved collagen-induced arthritis in mice. Compound 1q (AN4161) is considered to be a promising lead for novel anti-inflammatory agent with an excellent pharmacokinetic profile. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.08.096

文献信息

• Discovery and structure–activity relationships of 6-(benzoylamino)benzoxaboroles as orally active anti-inflammatory agents
  作者：Tsutomu Akama、Chen Dong、Charlotte Virtucio、Yvonne R. Freund、Daitao Chen、Matthew D. Orr、Robert T. Jacobs、Yong-Kang Zhang、Vincent Hernandez、Yang Liu、Anne Wu、Wei Bu、Liang Liu、Kurt Jarnagin、Jacob J. Plattner

  DOI：10.1016/j.bmcl.2013.08.096

  日期：2013.11

  Structure-activity relationships of 6-(benzoylamino)benzoxaborole analogs were investigated for the inhibition of TNF-alpha, IL-1 beta, and IL-6 from lipopolysaccharide stimulated peripheral blood mononuclear cells. Compound 1q showed potent activity against all three cytokines with IC50 values between 0.19 and 0.50 mu M, inhibited LPS-induced TNF-alpha and IL-6 elevation in mice and improved collagen-induced arthritis in mice. Compound 1q (AN4161) is considered to be a promising lead for novel anti-inflammatory agent with an excellent pharmacokinetic profile. (C) 2013 Elsevier Ltd. All rights reserved.